CXBS (Corix Bioscience) Ending Cash Position: $0.36 Mil (As of Sep. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Corix Bioscience Ending Cash Position?

Corix Bioscience CXBS -99.00% Ending Cash Position is $0.36 Mil as of Sep. 2017.

Corix Bioscience's Ending Cash Position for the quarter that ended in Sep. 2017 was $0.36 Mil.

Corix Bioscience's quarterly Ending Cash Position increased from Mar. 2017 ($0.12 Mil) to Jun. 2017 ($0.14 Mil) and increased from Jun. 2017 ($0.14 Mil) to Sep. 2017 ($0.36 Mil).

Corix Bioscience's annual Ending Cash Position stayed the same from Jan. 2014 ($0.00 Mil) to Jan. 2015 ($0.00 Mil) but then increased from Jan. 2015 ($0.00 Mil) to Dec. 2016 ($0.00 Mil).

Corix Bioscience Ending Cash Position Related Terms

Corix Bioscience Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience Ending Cash Position Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
Ending Cash Position
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.00 0.12 0.14 0.36

Corix Bioscience Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Corix Bioscience's Ending Cash Position for the fiscal year that ended in Dec. 2016 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.2+-0.198
=0.00

Corix Bioscience's Ending Cash Position for the quarter that ended in Sep. 2017 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0.145+0.216
=0.36

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.36 Mil mean?
Corix Bioscience (CXBS) has a Ending Cash Position of $0.36 Mil as of Sep. 2017. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's Ending Cash Position too high?
Corix Bioscience's current Ending Cash Position is $0.36 Mil.
How does Corix Bioscience's Ending Cash Position compare to BKIT and YBAO?
Corix Bioscience's Ending Cash Position of $0.36 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Corix Bioscience and its competitors. Corix Bioscience's current Ending Cash Position is $0.36 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current Ending Cash Position of $0.36 Mil. The current Ending Cash Position is $0.36 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current Ending Cash Position is $0.36 Mil as of Sep. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.